Biocryst Pharmaceuticals Inc (BCRX) Testing Investors’ Patience Right Now
Currently, there are 209.21M common shares owned by the public and among those 197.48M shares have been available to trade. The company’s stock has a 5-day price change of 32.57% and 44.75% over the past three months. BCRX shares are trading 46.68% year to date (YTD), with the 12-month market performance up to 141.36% higher. […]
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Seen Running Too Hot, Let’s Look At This More Closely
Currently, there are 208.54M common shares owned by the public and among those 197.48M shares have been available to trade. The company’s stock has a 5-day price change of 7.93% and 6.43% over the past three months. BCRX shares are trading 12.23% year to date (YTD), with the 12-month market performance up to 102.88% higher. […]
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) – Not A Clear Buying Opportunity?
Biocryst Pharmaceuticals Inc (BCRX) concluded trading on Thursday at a closing price of $8.22, with 3.31 million shares of worth about $27.18 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 9.31% during that period and on April 24, 2025 the price saw a […]
Are Analysts Expecting A Better 2020 For Biocryst Pharmaceuticals Inc (BCRX)?
Biocryst Pharmaceuticals Inc (BCRX) concluded trading on Thursday at a closing price of $6.41, with 4.1 million shares of worth about $26.26 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -10.97% during that period and on April 10, 2025 the price saw a […]
Better Times Ahead For Biocryst Pharmaceuticals Inc (NASDAQ: BCRX)?
Biocryst Pharmaceuticals Inc (BCRX) concluded trading on Thursday at a closing price of $7.69, with 2.95 million shares of worth about $22.68 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -2.90% during that period and on March 20, 2025 the price saw a […]
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Seen Running Too Hot, Let’s Look At This More Closely
Currently, there are 208.54M common shares owned by the public and among those 197.13M shares have been available to trade. Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, […]
Investors Should Take Note Of Biocryst Pharmaceuticals Inc. (BCRX)
Biocryst Pharmaceuticals Inc. (BCRX) concluded trading on Wednesday at a closing price of $5.57, with 4.17 million shares of worth about $23.21 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -19.74% during that period and on Wednesday the price saw a gain of […]
Stick With Biocryst Pharmaceuticals Inc. (BCRX). The Bull Are Alive And Well
The Vanguard Group, Inc. recently announced the acquisition of new stake in Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX). The institutional investor has increased its shareholding in the Healthcare company by 2.08% to 14.9 million shares with purchase of 0.3 million shares. This fresh investment now brings its stake to 7.28% valued currently at $87.61 million. In addition, […]
Is Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) Proving The Doubters Wrong?
Biocryst Pharmaceuticals Inc. (BCRX) concluded trading on 01/04/24 at a closing price of $6.46, with 3.96 million shares of worth about $25.57 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -7.18% during that period and on Thursday the price saw a gain of […]
Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) Stock In Prove Me State
The Vanguard Group, Inc. has recently announced that it has increased stake in Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) by 2.08%. After grabbing 14.9 million shares, the institutional investor is now in possession of 0.3 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 7.28% having worth around $87.61 million. […]
